Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 2 2Sarcoma 1Neuroma, Acoustic 1Neurilemmoma 1Neoplasm Metastasis 1Multiple Myeloma 1Meningioma 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 16Hydroxyurea 7Everolimus 7Bevacizumab 7lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 6Proton Therapy 6Specimen Handling 5pembrolizumab 4Surgical Procedures, Operative 4Radiosurgery 4Imatinib Mesylate 4Cyclophosphamide 42-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 4aldesleukin 3abemaciclib 3Tranexamic Acid 3Temozolomide 3Sunitinib 3Sodium Chloride 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Nivolumab 3Ga(III)-DOTATOC 390Y-octreotide, DOTA-Tyr(3)- 3vistusertib 2trametinib 2ribociclib 2fludarabine 2arginyllysine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Meningioma × HDAC-42 × Clear all
NCT02282917 2025-12-05

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Massachusetts Eye and Ear Infirmary

Phase EARLY_PHASE1 Terminated
7 enrolled 19 charts
CNS

Meningioma, Neurilemmoma, Neuroma, Acoustic, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡